search
Back to results

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Primary Purpose

Open-Angle Glaucoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
XEN45 (Glaucoma Gel Stent)
Sponsored by
AbbVie
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Open-Angle Glaucoma focused on measuring Open-Angle Glaucoma, Glaucoma, OAG, XEN45, Glaucoma Gel Stent, XEN45 Glaucoma Treatment System

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Glaucoma in the study eye.

    1. Study eye diagnosed with open-angle glaucoma uncontrolled by medical therapy
    2. Study eye that meet at least one of the following criteria:

      • Failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery or tube shunt) (a minimum of approximately 15 subjects will be enrolled)
      • Failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode therapy)
      • Have neovascular glaucoma
      • Have any other condition (e.g., conjunctival scarring, uveitis) in which a conventional incisional glaucoma surgery like trabeculectomy would be more likely to fail than for a person with uncomplicated primary open-angle glaucoma (OAG).

      Note: To allow for a subgroup of participants who only have OAG uncontrolled by medical therapy (non-refractory glaucoma), a maximum of 10 participants who meet only criterion a (and not b) will be enrolled.

      Exclusion Criteria:

  • A lack of healthy conjunctiva showing free mobility (free of scarring or evidence of prior surgery) in the target area.
  • Excessive intraoperative bleeding, such that visualization in the study eye is impaired.
  • Any anatomy or finding in the study eye that limits the investigator's ability to visualize the anterior chamber, angle, or target area of the conjunctiva.
  • Other surgical complication that in the opinion of the investigator could impede proper placement of the Gel Stent.

Sites / Locations

  • Vold Vision /ID# 245285Recruiting
  • UCLA Doheny Eye Center /ID# 227587Recruiting
  • Ventura Ophthalmology /ID# 227585Recruiting
  • East Coast Institute for Research /ID# 255508Recruiting
  • Center for Sight - Sarasota /ID# 227577Recruiting
  • Georgia Eye Partners /ID# 245203
  • Stiles Eyecare Excellence /ID# 227576Recruiting
  • Johns Hopkins /ID# 245355Recruiting
  • Washington University-School of Medicine /ID# 245452Recruiting
  • New York University, Langone Health /ID# 227583Recruiting
  • Fichte Endl & Elmer Eyecare Ophthalmology PC /ID# 245165Recruiting
  • Oklahoma Eye Surgeons /ID# 246840Recruiting
  • Ophthalmic Partners, PC /ID# 245367Recruiting
  • Kremer Eye Center - King of Prussia /ID# 245573Recruiting
  • Glaucoma Associates of Texas /ID# 227580Recruiting
  • University of Texas Southwestern Medical Center /ID# 246848Recruiting
  • El Paso Eye Surgeons, P.A. /ID# 227575Recruiting
  • Eye associates /ID# 227572Recruiting
  • University of Utah /ID# 245324Recruiting
  • Northern Virginia Ophthalmology Associates -Falls Church /ID# 246925Recruiting
  • Eye Surgery Associates /ID# 252207Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

XEN45 (Glaucoma Gel Stent)

Arm Description

Participants will receive XEN45 implanted using an ab externo approach on Day 1.

Outcomes

Primary Outcome Measures

Percentage of Participants Achieving Effectiveness of XEN45
Effectiveness is defined as achieving 20% or more reduction of intraocular pressure (IOP) from baseline and on the same or fewer number of glaucoma medications than at baseline without secondary surgical intervention for IOP (SSII).

Secondary Outcome Measures

Full Information

First Posted
June 6, 2022
Last Updated
October 9, 2023
Sponsor
AbbVie
search

1. Study Identification

Unique Protocol Identification Number
NCT05411198
Brief Title
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Official Title
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Ab Externo Implantation of Glaucoma Gel Stent
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 22, 2022 (Actual)
Primary Completion Date
August 15, 2025 (Anticipated)
Study Completion Date
August 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AbbVie

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States. All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open-Angle Glaucoma
Keywords
Open-Angle Glaucoma, Glaucoma, OAG, XEN45, Glaucoma Gel Stent, XEN45 Glaucoma Treatment System

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
65 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
XEN45 (Glaucoma Gel Stent)
Arm Type
Experimental
Arm Description
Participants will receive XEN45 implanted using an ab externo approach on Day 1.
Intervention Type
Device
Intervention Name(s)
XEN45 (Glaucoma Gel Stent)
Intervention Description
Ab externo implant
Primary Outcome Measure Information:
Title
Percentage of Participants Achieving Effectiveness of XEN45
Description
Effectiveness is defined as achieving 20% or more reduction of intraocular pressure (IOP) from baseline and on the same or fewer number of glaucoma medications than at baseline without secondary surgical intervention for IOP (SSII).
Time Frame
Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Glaucoma in the study eye. Study eye diagnosed with open-angle glaucoma uncontrolled by medical therapy Study eye that meet at least one of the following criteria: Failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma filtering surgery or tube shunt) (a minimum of approximately 15 subjects will be enrolled) Failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode therapy) Have neovascular glaucoma Have any other condition (e.g., conjunctival scarring, uveitis) in which a conventional incisional glaucoma surgery like trabeculectomy would be more likely to fail than for a person with uncomplicated primary open-angle glaucoma (OAG). Note: To allow for a subgroup of participants who only have OAG uncontrolled by medical therapy (non-refractory glaucoma), a maximum of 10 participants who meet only criterion a (and not b) will be enrolled. Exclusion Criteria: A lack of healthy conjunctiva showing free mobility (free of scarring or evidence of prior surgery) in the target area. Excessive intraoperative bleeding, such that visualization in the study eye is impaired. Any anatomy or finding in the study eye that limits the investigator's ability to visualize the anterior chamber, angle, or target area of the conjunctiva. Other surgical complication that in the opinion of the investigator could impede proper placement of the Gel Stent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
ABBVIE CALL CENTER
Phone
844-663-3742
Email
abbvieclinicaltrials@abbvie.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ABBVIE INC.
Organizational Affiliation
AbbVie
Official's Role
Study Director
Facility Information:
Facility Name
Vold Vision /ID# 245285
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72704
Country
United States
Individual Site Status
Recruiting
Facility Name
UCLA Doheny Eye Center /ID# 227587
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Individual Site Status
Recruiting
Facility Name
Ventura Ophthalmology /ID# 227585
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Individual Site Status
Recruiting
Facility Name
East Coast Institute for Research /ID# 255508
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256-9680
Country
United States
Individual Site Status
Recruiting
Facility Name
Center for Sight - Sarasota /ID# 227577
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Individual Site Status
Recruiting
Facility Name
Georgia Eye Partners /ID# 245203
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Individual Site Status
Completed
Facility Name
Stiles Eyecare Excellence /ID# 227576
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66213
Country
United States
Individual Site Status
Recruiting
Facility Name
Johns Hopkins /ID# 245355
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20817
Country
United States
Individual Site Status
Recruiting
Facility Name
Washington University-School of Medicine /ID# 245452
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
New York University, Langone Health /ID# 227583
City
New York
State/Province
New York
ZIP/Postal Code
10017
Country
United States
Individual Site Status
Recruiting
Facility Name
Fichte Endl & Elmer Eyecare Ophthalmology PC /ID# 245165
City
Niagara Falls
State/Province
New York
ZIP/Postal Code
14304
Country
United States
Individual Site Status
Recruiting
Facility Name
Oklahoma Eye Surgeons /ID# 246840
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Individual Site Status
Recruiting
Facility Name
Ophthalmic Partners, PC /ID# 245367
City
Bala-Cynwyd
State/Province
Pennsylvania
ZIP/Postal Code
19004
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Coordinator
Phone
484-434-2706
Facility Name
Kremer Eye Center - King of Prussia /ID# 245573
City
King Of Prussia
State/Province
Pennsylvania
ZIP/Postal Code
19406
Country
United States
Individual Site Status
Recruiting
Facility Name
Glaucoma Associates of Texas /ID# 227580
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Texas Southwestern Medical Center /ID# 246848
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-7208
Country
United States
Individual Site Status
Recruiting
Facility Name
El Paso Eye Surgeons, P.A. /ID# 227575
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Individual Site Status
Recruiting
Facility Name
Eye associates /ID# 227572
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Utah /ID# 245324
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112-5500
Country
United States
Individual Site Status
Recruiting
Facility Name
Northern Virginia Ophthalmology Associates -Falls Church /ID# 246925
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042-3013
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Coordinator
Phone
703-534-3900, ext 5
Facility Name
Eye Surgery Associates /ID# 252207
City
East Melbourne
State/Province
Victoria
ZIP/Postal Code
3002
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site Coordinator
Phone
+61399988337

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD Sharing Time Frame
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD Sharing Access Criteria
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD Sharing URL
https://vivli.org/ourmember/abbvie/
Links:
URL
https://www.rxabbvie.com/
Description
Related info

Learn more about this trial

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

We'll reach out to this number within 24 hrs